Company
AstraZeneca PLC
LON:AZN
AstraZeneca is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease. AstraZeneca has over 67,000 empolyees and operates in over 100 countries with growing presence in important emerging markets.
1076 stories · page 3 of 11
Archive
FTSE 100 Live: Stocks fade after bright start to end little changed
At the close, London's blue-chip index was down 2.12 points at 7,542.77 while the FTSE 250 was down 88.27 points, 0.5%, at 18,662.12
Archive
FTSE 100 Live: Stocks end on a high after ECB says rate hikes are over
London's main index finished the week on a high note
Archive
FIVE at FIVE: AstraZeneca boss denial; $53 billion oil takeover; BT environmental calls; Shoplifting crackdown; FTSE 100 falls
Here’s Proactive’s round-up of the top financial stories of the day, with helpful links taking you directly to the news
AstraZeneca settles Nexium heartburn drug cases for US$425m
AstraZeneca denied liability and said it has settled to avoid costly litigation
AstraZeneca bounces back from reports CEO Soriot is eyeing exit
There are a number of potential successors on the board if the news turns out to be true
Barclays starts bank season while UK top dog Astra reports: Thursday agenda
AstraZeneca, Barclays, Currys, London Stock Exchange,Taylor Wimpey, Unilever, WPP and J Sainsbury plus more all report Thursday
Big Pharma earnings bonanza could shape sector going forward: PREVIEW
Eli Lilly and Company, Merck & Co, AstraZeneca PLC, Sanofi and Bristol-Myers Squibb are all expected to report earnings before the bell on Thursday
FIVE at FIVE: AstraZeneca jumps Pfizer, Royal Mail confusion, LVMH soars and Lloyds upgraded
Here’s Proactive’s round-up of the top financial stories of the day, with helpful links taking you directly to the news
AstraZeneca earnings per share forecasts raised by Barclays
Barclays raised AstraZeneca's earnings per share forecasts after the biotech company penned a new deal on Tuesday
AstraZeneca premium justified by long-term potential says broker
Pipeline prospects give a 13,000p/share target says Shore Capital
Brexit driving UK manufacturers to turn away from foreign suppliers
40% of UK manufacturers have looked to domesticate supply lines, while many EU firms are complacent about trading with British companies, Make UK says
AstraZeneca to acquire CinCor for US$1.8bn
CinCor's key treatment tackles the effects of diseases such as hypertension, diabetes and vascular defects
AstraZeneca posts mixed results from lung cancer trial
Imfinzi missed its primary endpoint but achieved its secondary result
FIVE at FIVE: UK inflation eases; BT price changes probed by Ofcom; AstraZeneca assessed; Sam Bankman-Fried denied bail
Here’s Proactive’s round-up of the top financial stories of the day, with helpful links taking you directly to the news
AstraZeneca attractive in near term but patent cliffs loom, says broker
AstraZeneca's project pipelines means it has positive near-term prospects, but Jefferies lowered earnings forecasts
AstraZeneca a ‘buy’ for project pipeline potential – broker
Shore reiterated a price target of £127 by the end of 2023, up from almost £114 currently.
Archive
AstraZeneca a buy after strong quarter- Shorecap
Shore Capital Group Ltd reiterated its recommendation that AstraZeneca was a buy after strong quarterly results
AstraZeneca raises earnings guidance as profit margins improve
Last year's acquisition of Alexion and a "favourable product mix" had a positive impact
AstraZeneca receives backing for new rescue inhaler
The new product is being developed jointly by AZ and UK group Avillion
AstraZeneca says Beyfortus gets EU approval for respiratory virus in infants
Beyfortus is the first and only single-dose respiratory syncytial virus (RSV) passive immunisation for the broad infant population
AstraZeneca shares will get lift from heartburn drug litigation closure, says Citi
The UK pharma is one of several firms embroiled in US legal action over possible kidney damage
AstraZeneca trial of Fasrena fails to help with eosinophilic esophagitis swallowing problems
Eosinophilic esophagitis is a rare, progressive, chronic inflammatory disease of the oesophagus, which can lead to difficulty with swallowing, pain, food getting stuck and anxiety
AstraZeneca says Imjudo-Imfinzi combination approved for advanced liver cancer in US
The HIMALAYA Phase III trial showed that a single priming dose of Imjudo added to Imfinzi reduced the risk of death by 22% compared with sorafenib
AstraZeneca earnings to fall due to lower sales and higher costs
AstraZeneca core average earnings per share will fall 5.5% predicts Credit Suisse
AstraZeneca set for strong third-quarter; brokers think the stock is worth £125
Shore Capital is one of 21 banks and brokers following AZ that are bullish on the outlook for the Anglo-Swedish drugs giant and its share price
AstraZeneca sees COVID-19 vaccine suffer a setback in nasal spray trial
An antibody response in the respiratory mucous membranes was seen in only a minority of participants in the trial, which was in the first of usually three phases of clinical testing, the University of Oxford said in a statement
AstraZeneca gets its third regulatory green light in a matter of weeks for asthma drug
The treatment has been approved in Japan for severe bronchial asthma where high-dose traditional corticosteroids don’t work
AstraZeneca wins European approval for Ultomiris autoimmune disease treatment
The nod from the European Commission paves the way for the first long-acting C5 inhibitor for generalised myasthenia gravis
AstraZeneca receives China green light for Lynparza
The drug will be used as a maintenance treatment in women with an advanced form of ovarian cancer
AstraZeneca says Evusheld approved for treatment of COVID-19 in EU
Evusheld has been shown to significantly reduce the risk of severe COVID-19 or death
AstraZeneca gets EU backing for COVID-19 treatment and RSV drug
If Beyfortus receives marketing approval, it would be the first single-dose preventative therapy for RSV for infants
Archive
Market movers: Property groups fall as Goldman/JPMorgan reduce price targets
A look at some risers and fallers in the market today.
Archive
FTSE 100 closes in the red as the investor gloom continues
Britain's blue-chip index finished around 45 points lower, or 0.62%, at 7,236 on the day
AstraZeneca wins injunction preventing former executive from joining GSK
AstraZeneca secured a victory in its battle with GSK in its executive tug of war at the last moment - at least for now
AstraZeneca's Farxiga successfully used to treat heart failure
The new indication could increase Farxiga's addressable market by 50%
AstraZeneca looking for bolt-on acquisitions
Pascal Soriot said the FTSE 100 giant is particularly interested in firms that specialise in oncology and cardiovascular treatments
AstraZeneca breast cancer drug performs well in latest trial
The results of the confirmatory assessment mirrored earlier positive data
AstraZeneca chemotherapy signed off for use in people with lung cancer
The US Food & Drug Administration has provided its seal of approval for Enhertu
AstraZeneca breast cancer drug gets the green light
The Anglo-Swedish drugs giant has hailed Enhertu as as potentially transformational treatment
AstraZeneca follows the trend in the sector to upgrade guidance as Covid vaccines sales show resilience
Instead of dropping by up to a quarter, sales of Vaxzevria will now be flat